Posted by Michael Wonder on 17 Jun 2017
Institute for Clinical and Economic Review report finds inadequate evidence to distinguish between anabolic therapies for osteoporosis
16 June 2017 - Cost-effectiveness analyses find prices too high to align with added benefit to patients.
The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of two anabolic agents for treatment of osteoporosis in postmenopausal women who are at high risk for fracture: abaloparatide (Tymlos, Radius Health) and teriparatide (Forteo, Eli Lilly). The report also includes a summary of trial results of a third anabolic agent, romosozumab (Amgen and UCB), which is currently under review by the FDA.
This Evidence Report will be the subject of an upcoming public meeting of the California Technology Assessment Forum on 30 June 2017.
